302 related articles for article (PubMed ID: 24106691)
1. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.
Diamantopoulos AP; Hetland H; Myklebust G
Biomed Res Int; 2013; 2013():120638. PubMed ID: 24106691
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series.
Adizie T; Christidis D; Dharmapaliah C; Borg F; Dasgupta B
Int J Clin Pract; 2012 Sep; 66(9):906-9. PubMed ID: 22897467
[TBL] [Abstract][Full Text] [Related]
3. Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice.
Lally L; Spiera R
Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):803-812. PubMed ID: 31427056
[TBL] [Abstract][Full Text] [Related]
4. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.
Schmidt J; Warrington KJ
Drugs Aging; 2011 Aug; 28(8):651-66. PubMed ID: 21812500
[TBL] [Abstract][Full Text] [Related]
5. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach.
Borresen SW; Thorgrimsen TB; Jensen B; Hilsted L; Bartels EM; Feldt-Rasmussen U; Locht H
Rheumatology (Oxford); 2020 Oct; 59(10):2764-2773. PubMed ID: 32031663
[TBL] [Abstract][Full Text] [Related]
6. Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis. State of the art and perspectives.
Ferraccioli GF; Di Poi E; Damato R
Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S58-60. PubMed ID: 10948766
[TBL] [Abstract][Full Text] [Related]
7. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.
Emamifar A; Ellingsen T; Hermann AP; Hess S; Gerke O; Ahangarani Farahani Z; Syrak Hansen P; Jensen Hansen IM; Thye-Rønn P
Sci Rep; 2021 Mar; 11(1):6220. PubMed ID: 33737697
[TBL] [Abstract][Full Text] [Related]
9. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.
Gonzalez-Gay MA; Garcia-Porrua C; Miranda-Filloy JA; Martin J
Drugs Aging; 2006; 23(8):627-49. PubMed ID: 16964987
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy.
Martinez-Taboada VM; Bartolome MJ; Fernandez-Gonzalez MD; Blanco R; Rodriguez-Valverde V; Lopez-Hoyos M
Rheumatology (Oxford); 2003 Sep; 42(9):1055-61. PubMed ID: 12730520
[TBL] [Abstract][Full Text] [Related]
11. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
[TBL] [Abstract][Full Text] [Related]
12. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.
van der Geest KS; Abdulahad WH; Chalan P; Rutgers A; Horst G; Huitema MG; Roffel MP; Roozendaal C; Kluin PM; Bos NA; Boots AM; Brouwer E
Arthritis Rheumatol; 2014 Jul; 66(7):1927-38. PubMed ID: 24623536
[TBL] [Abstract][Full Text] [Related]
13. Treatment of polymyalgia rheumatica/giant cell arteritis.
Kyle V
Baillieres Clin Rheumatol; 1991 Dec; 5(3):485-91. PubMed ID: 1807823
[TBL] [Abstract][Full Text] [Related]
14. Polymyalgia rheumatica.
Lestico MR; Boh LE; Schuna AA
Clin Pharm; 1993 Aug; 12(8):571-80. PubMed ID: 8222521
[TBL] [Abstract][Full Text] [Related]
15. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica.
González-Gay MA; García-Porrúa C; Vázquez-Caruncho M
J Rheumatol; 1998 Sep; 25(9):1750-5. PubMed ID: 9733456
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of polymyalgia rheumatica and giant cell arteritis.
Salvarani C; Pipitone N; Versari A; Hunder GG
Nat Rev Rheumatol; 2012 Sep; 8(9):509-21. PubMed ID: 22825731
[TBL] [Abstract][Full Text] [Related]
17. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
[TBL] [Abstract][Full Text] [Related]
18. [A case of giant cell arteritis after prednisolone dose reduction during treatment of polymyalgia rheumatica].
Yamashita M; Aoki A; Kobayashi H; Wakiya M; Nakatsugawa M
Nihon Ronen Igakkai Zasshi; 2023; 60(4):440-447. PubMed ID: 38171762
[TBL] [Abstract][Full Text] [Related]
19. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.
Askling J; Klareskog L; Hjalgrim H; Baecklund E; Björkholm M; Ekbom A
Ann Rheum Dis; 2005 Dec; 64(12):1765-8. PubMed ID: 15843445
[TBL] [Abstract][Full Text] [Related]
20. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.
Braun N; Fritz P; Rieth A; Schroth W; Kimmel M; Biegger D; Zakim D; Alscher MD
J Rheumatol; 2009 Oct; 36(10):2269-76. PubMed ID: 19684157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
